X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NTX-001 is a novel E3 ubiquitin-protein ligase CBL-B inhibitor small molecule drug which is under phase 2 clinical development for the treatment of Transected Peripheral Nerves.
Lead Product(s): NTX-001
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NTX-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
NTX-001 is a novel E3 ubiquitin-protein ligase CBL-B inhibitor small molecule drug which is under phase 2 clinical development for the treatment of Transected Peripheral Nerves.
Lead Product(s): NTX-001
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NTX-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
NTX-001 is a combination drug-device product, a 505b2 product (comprised of previously approved components) provided as sterile solutions for the treatment and prevention of facial paralysis.
Lead Product(s): NTX-001
Therapeutic Area: Neurology Product Name: NTX-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2022
Details:
Company announced activation of it first clinical site of its Phase 2 Multicenter, Randomized, Controlled Study Evaluating the Safety and Efficacy of NTX-001 versus Standard of Care in Patients with Acute Single Transected Peripheral Nerve Injuries of the Upper Extremities.
Lead Product(s): NTX-001
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NTX-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Neuraptive's franchise therapeutic product, NTX-001, in the treatment of patients with peripheral nerve injuries.
Lead Product(s): NTX-001
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
Neuraptive will conduct a Phase 2 study evaluating the safety and efficacy of NTX-001 vs standard of care in patients with acute single transected peripheral nerve injuries of the upper extremities.
Lead Product(s): NTX-001
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
